HSE - PCRS

Application Details

HSE Application ID

HSE100102

HTA Number

26018

HTA Link

https://www.ncpe.ie/durvalumab-imfinzi-hta-id-26018/

Drug

durvalumab

Brand

Imfinzi®

Applicant

AstraZeneca

Indication Applied For

Durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR).

Application Date

09/04/2026

Marketing Authorisation Date

26/07/2024

Application Status

Proposal from Applicant Under Review

08/07/2026

Awaiting Proposal from Applicant

02/07/2026

Applicant Meeting Held with CPU

02/07/2026

Rapid Review Completed

15/05/2026

Rapid Review Commissioned

10/04/2026

Pricing and Reimbursement Application Complete

09/04/2026

New Search